Importance of pH control in the management of GERD

Archives of Internal Medicine

Volumn 159, Issue 7, 1999, Pages 649-657

  Hunt, Richard H ^a  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; CIMETIDINE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE;

DOSE RESPONSE; DRUG EFFICACY; EPIGASTRIC PAIN; ESOPHAGITIS; ESOPHAGUS INJURY; ESOPHAGUS PH; GASTROESOPHAGEAL REFLUX; HUMAN; LOWER ESOPHAGUS SPHINCTER; PRIORITY JOURNAL; REVIEW; STOMACH PH;

DRUG ADMINISTRATION SCHEDULE; GASTRIC ACID; GASTROESOPHAGEAL REFLUX; HISTAMINE H2 ANTAGONISTS; HUMANS; HYDROGEN-ION CONCENTRATION; MUCOUS MEMBRANE; PROTON PUMPS;

EID: 0033548841     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.159.7.649     Document Type: Review

References (75)

1. Raiha I, Impivaara O, Seppala M, Sourander L. Prevalence and characteristics of symptomatic gastroesophageal reflux disease in the aged. J Am Geriatr Soc. 1992;50:1209-1211.
2. Petersen H. The prevalence of gastro-oesophageal reflux disease. Scand J Gastroenterol, 1995;211 (30 suppl):5-6.
3. Norrelund N, Petersen PA. Prevalence of gastro-oesophageal reflux-like dyspepsia. In: Program and abstracts of the International Congress of Gastroenterology; September 4-10, 1988; Rome, Italy. Abstract A1031.
4. Jones R, Lydeard S. Prevalence of symptoms of dyspepsia in the community. BMJ. 1989;298: 30-32.
5. Lydeard S, Jones R. Factors affecting the decision to consult with dyspepsia, comparison of consulters and non-consulters. J R Coll Gen Pract. 1989;39:495-498.
6. Fass R, Yalam J, Camargo L, Grade, A, Sampliner RE. Assessment of esophageal afferent chemosensitivity in elderly versus young patients with gastroesophageal reflux disease. Gastroenterology. 1997;112:A114.
7. Raiha I, Impivaara O, Seppala M, Knuts LR, Sournader L. Determinants of symptoms suggestive of gastroesophageal reflux disease in the elderly. Scand J Gastroenterol. 1993;28:1011-1014.
8. Van Deventer G, Kanemoto E, Kuznicki JT, Heckert DC, Schulte MC. Lower esophageal sphincter pressure, acid suppression and blood gastrin after coffee consumption. Dig Dis. 1992;37: 558-569.
9. Kahrilas PJ. Cigarette smoking and gastroesophageal reflux disease. Dig Dis. 1992;10:61-71.
10. Nebel OT, Castell DO. Inhibition of the lower oesphageal sphincter by fat: a mechanism for fatty food intolerance. Gut. 1973;14:270-274.
11. Richter JE, Castell DO. Drugs, foods, and other substances in the cause and treatment of reflux esophagitis. Med Clin North Am. 1981;65: 1223-1234.
12. Sloan S, Rademaker AW, Kahrilas PJ. Determinants of gastroesophageal junction incompetence: hiatal hernia, lower esophageal sphincter, or both? Ann Intern Med. 1992;17:977-982.
13. Radmark T, Pettersson GB. The contribution of the diaphragm and an intrinsic sphincter to the gastroesophageal antireflux barrier an experimental study in the dog. Scand J Gastroenterol. 1989; 24:85-94.
14. Ott DJ, Wu WC, Gelfand DW. Reflux esophagitis revisited: prospective analysis of radiologic accuracy. Gastrointest Radiol. 1981;6:1-7.
15. Sloan S, Kahrilas PJ. Impairment of esophageal emptying with hiatal hernia. Gastroenterology. 1991;100:596-605.
16. Zanimotto G, Costantini M, DiMario F, et al. Oesophagitis and pH of the refluxate: experimental and clinical study. Gut. 1990;31:A602.
17. Hirschowitz BI. A critical analysis, with appropriate controls, of gastric acid and pepsin secretion in clinical esophagitis. Gastroenterology. 1991; 101:1149-1158.
18. Orlando RC. Why is the high grade inhibition of gastric acid secretion afforded by proton pump inhibitors often required for healing of reflux esophagitis? an epithelial perspective. Am J Gastroenterol. 1996;91:1692-1696.
19. Bell NJV, Burget D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for management of gastro-oesophageal reflux disease. Digestion. 1992;51(suppl 1):59-67.
20. Howden CW, Burget DW, Hunt RH. Appropriate acid suppression for optimal healing of duodenal ulcer and gastro-oesophageal reflux disease. Scand J Gastroenterol. 1994;29(suppl 201):79-82.
21. Vaezi MF, Richter JE. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology. 1996; 111:1192-1199.
22. Smith JL, Operkun AR, Larkai E, Graham DY. Sensitivity of esophageal mucosa to pH in gastroesophageal reflux disease. Gastroenterology. 1989; 96:683-689.
23. Jimenez P, Lanas A, Piazuelo E, Esteva F, Sainz R. Small decreases in pH inhibit both proliferation and restitution of esophageal epithelial cells. Gastroenterology. 1997;112:A161.
24. Chiba N, de Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophagsal reflux diseases meta-analysis. Gastroenterology. 1997;112:1798-1810.
25. Grove O, Bekker C, Jeppe-Hansen MG, et al. Ranitidine and high-dose antacid in reflux oesophagitis. Scand J Gastroenterol. 1985;20:457-461.
26. Weberg R, Berstad A. Symptomatic effect of a low-dose antacid regimen in reflux oesophagitis. Scand J Gastroenterol. 1989;24:401-406.
27. Hatlebakk JG, Berstad A. Pharmacokinetic optimization in the treatment of gastro-oesophageal reflux disease. Clin Pharmacokinet. 1996;31: 386-406.
28. 2-antagonists alone completely block food stimulated acidity? Eur J Gastroenterol Hepatol. 1991; 3:533-537.
29. 2-antagonist treatment. Gastroenterology. 1991;100:599-606.
30. Nwokolo CU, Smith JT, Gavey C, et al. Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine, or ranitidine. Aliment Pharmacol Ther. 1990;4(suppl 1): 29-45.
31. Kahrilas PJ, Fennerty B, Joelsson B. High-versus standard-dose ranitidine for control of heart-burn in poorly responsive acid reflux disease: a prospective controlled trial. Am J Gastroenterol. 1999;94:92-97.
32. Sontag SJ. Rolling review: gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 1993:7: 293-312.
33. Howden CW, Merdith PA, Forrest JAH, et al. Oral pharmacokinetics of omeprazole. Eur J Clin Pharmacol. 1984;26:641-643
34. Delhotal Landes B, Petite JP, Flouvat B. Clinical pharmacokinetics of lansoprazole. Clin Pharmacokinet 1995;28:458-470.
35. Pue MA, Laroche J, Meineke I, de Mey C. Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects. Eur J Clin Pharmacol. 1993;44: 575-578.
36. Slum RA. Lansoprazole and omeprazole in the treatment of acid peptic disorders. Am J Health Syst Pharm. 1996;53:1401-1415.
37. Howden CW. Clinical pharmacology of omeprazole. Clin Pharmacokinet. 1991;20:38-49.
38. Simon B, Muller P, Marinis E, et al. Effect of repeated oral administration on BY 1023/SK& F96022: a new substituted benzimidazole derivative on pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man. Aliment Pharmacol Ther. 1990;40:373-380.
39. Bell NJV, Hunt RH. Progress with proton pump inhibitors. Yale J Biol Med. 1992;65:649-657.
40. Atanassotf PG, Brull SJ, Weiss BM, Landefeld K, Alon E, Rohling R. The time course of gastric pH changes induced by omeprazole and ranitidine: a 24-hour dose-response study. Anesth Analg. 1995; 80:975-979.
41. Houben GM, Hooi J, Hameeteman W, Stockbrugger RW. Twenty-four hour intragastric acidity: 300 mg ranitidine b.d., 20 mg omeprazole a.m., 40 mg omeprazole o.m. vs. placebo. Aliment Pharmacol Ther. 1995;9:649-654.
42. Slum RA, Shi H, Karol M, Greski-Rose P, Hunt RH. The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion. Clin Ther. 1997;19:1013-1023.
43. Fraser AG, Sawyer AM, Hudson M, Smith M, Pounder RE. Effects of ranitidine 150 mg four times a day on 24-hour intragastric acidity and 24-hour plasma gastrin concentration. Dig Dis Sci. 1994;39:91-96.
44. Bisson C, St Laurent M, Michaud JT, LeBel M. Pharmacokinetics and pharmacodynamics of ranitidine and famotidine in healthy elderly subjects: a double-blind, placebo-controlled comparison. Pharmacotherapy. 1993;13:3-9.
45. Sakaguchi M, Ashida K, Umegaki E, Miyoshi H, Katsu K. Suppressive action of lansoprazole on gastric acidity and its clinical effect in patients with gastric ulcers: comparison with famotidine. J Clin Gastroenterol. 1995;20(suppl 2):S27-S31.
46. Hurlimann S, Abbuhl B, Inauen W, Halter F. Comparison of acid-inhibition by either oral high-dose ranitidine or omeprazole. Aliment Pharmacol Ther. 1994;8:193-201.
47. Savarino V, Mela GS, Zentilin P, Cuteka P, Mele R, Celle G. Twenty-four hour control of gastric acidity by twice-daily doses of placebo, nizatidine 150 mg, nizatidine 300 mg, and ranitidine 300 mg. J Clin Pharmacol. 1993;33:70-74.
48. Meyer M, Meier R, Drewe J. Effect of lansoprazole and ranitidine on gastric acidity in healthy volunteers. Gastroenterology. 1997;112(suppl): A219.
49. Reill L, Erhardt F, Fishcher R, Londong W. Intragastric pH and serum gastrin after one treatment with pantoprazole, ranitidine, or placebo in man. Gastroenterology. 1993;104(4 suppl):A177.
50. Dammann HG, Fuchs W, Richter G, Burkhardt F, Wolf N, Walter ThA. Lansoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion. Aliment Pharmacol Ther. 1997;11: 359-364.
51. Spencer CM, Faulds D. Lansoprazole: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders. Drugs. 1994;48: 404-430.
52. McTavish D, Buckley M-T, Heel RC. Omeprazole: an updated review of its pharmacology and therapeutic use in acid-related disorders. Drugs. 1991; 42:138-170.
53. Bell NJ, Hunt RH. Time to maximum effect of lansoprazole on gastric pH in normal male volunteers. Aliment Pharmacol Ther. 1996;10: 897-904.
54. Bruley des Varannes S, Levy P, Lartigue S, Dellatolas F, LeMaire M. Comparison of lansoprazole with omeprazole on 24-hour intragastric pH, acid secretion and serum gastrin in healthy volunteers. Aliment Pharmacol Ther. 1994;8: 309-314.
55. Tolman KG, Sanders SW, Buchi KN, Karol MD, Jennings DE, Ringham GL. The effects of oral doses of lansoprazole and omeprazole on gastric pH. J Clin Gastroenterol. 1997;24:65-70.
56. Meyer M, Meier R. Effect of low-dose lansoprazole and omeprazole on gastric acidity in Helicobacter pylori-negative volunteers. Gastroenterology. 1998;114:A227.
57. Takeda H, Hokari K, Asaka M. Evaluation of the effect of lansoprazole in suppressing acid secretion using 24-hour intragastric pH monitoring. J Clin Gastroenterol. 1995;20(suppl 1):S57-S59.
58. Brunner G, Danz-Neeff H, Athmann C, Samayoa N. Comparison of pantoprazole (40 mg SID) versus omeprazole (40 mg SID) on intragastric pH and serum gastrin in healthy volunteers. Gastroenterology. 1997;112(4suppl):A78.
59. Florent C, Forestier S, Akrour O. Comparison of the 24-hour intragastric pH profiles after 30 mg lansoprazole and 40 mg pantoprazole in healthy volunteers. Gastroenterology. 1996;110(4 suppl): A109.
60. 2-receptor antagonists. Gastroenterology. 1998;114:A155. Abstract G0633.
61. Bardhan KD, Hawkey CJ, Long R, et al. Lansoprazole versus ranitidine for the treatment of reflux esophagitis. Aliment Pharmacol Ther. 1995; 9:145-151.
62. Koop H, Schepp W, Dammann HG, Schneider A, Luhmann R, Classen M. Comparative trial of pantoprazole and ranitidine in the treatment of reflux esophagitis: results of a German multicenter study. J Clin Gastroenterol. 1995;20:192-195.
63. Dammann HG, Hahn EG, Adler G, et al. Pantoprazole is more effective than famotidine in acute gastro-esophageal reflux disease. Gastroenterelogy. 1996;110(suppl4):AB9.
64. Robinson M, Kogut O, Jennings D, et al. Lansoprazole heals erosive esophagitis better than ranitidine Gastroenterology. 1992;102:A153.
65. Feldman M, Harford WW, Fisher RS, et al. Treatment of reflux esophagitis resistant to H2-receptor antagonists with lansoprazole, a new H+/ K+-ATPase inhibitor: a controlled double-blind study. Am J Gastroenterol. 1993;88:1212-1217.
66. 2 receptor antagonists. Aliment Phamacol Ther. 1990;4:145-155.
67. Bianchi-Porro G, Pace F, Sangaletti O. Omeprazole or ranitidine at standard or double doses in the treatment of patients with refractory reflux esophagitis. Gut. 1990;31:A1189. Abstract.
68. 2-receptor antagonist therapy. Gastroenterology. 1992;102:A167. Abstract.
69. 2-blocker-resistant esophagitis. Dig Dis Sci. 1991;36: 552-557.
70. Lundell L, Backman L, Ekstrom P, et al. Prevention of relapse of reflux esophagitis after endoscopic healing: the efficacy and safety of omeprazole compared to ranitidine. Scand J Gastroenterol. 1991;26:248-256.
71. Hetzel DJ. Controlled clinical trials of omeprazole in the long-term management of reflux disease. Digestion. 1992;51(suppl 1):35-42.
72. Vigneri S, Termini R, Leandro G. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med. 1995;333:1106-1110.
73. Hatlebakk JG, Berstad A, Carling LE, et al. Lansoprazole versus omeprazole in short-term treatment of reflux esophagitis. Scand J Gastroenterol. 1993;28:224-228.
74. Mee AS, Rowley JL, and the Lansoprazole Clinical Research Group. Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole. Aliment Pharmacol Ther. 1996; 10:757-763.
75. Castell DO, Richter JF, Robinson M, Sontag SJ, Haber MM. Efficacy and safety of lansoprazole in the treatment of erosive esophagitis. Am J Gastroenterol. 1996;91:1749-1756.